a 10-patient feasibility study to determine the appropriate dosing, to assess safety and tolerability, and to measure the effect size of the
intervention to calculate sample size of the efficacy
study. In total, 44 patients with treated type 2 diabetes were enrolled in the randomized, double-blind, parallel-group efficacy study, with half allocated to the treatment arm of 321 mg of flavanols per dose three times daily.